ÂÜÀòÂÒÂ×

Kevin Eggan is currently the CSO/SVP Head of Research and Early Development at BioMarin Pharmaceutical Inc. Kevin founded EnClear Therapies in 2018 and QurAlis in 2017. In 2013, they also founded Q-State Biosciences. Prior to these roles, they held various positions at Harvard University, starting as a Harvard Junior Fellow in 2003 and progressing to Professor. Kevin also served as a Principal Investigator at Harvard Stem Cell Institute. Additionally, they were a SAB member at Ipierian from 2009 to 2014.

Kevin Eggan obtained their Bachelor of Science (BS) degree in Microbiology and Immunology from the University of Illinois Urbana-Champaign from 1992 to 1996. Kevin then pursued further education at the Massachusetts Institute of Technology, where they completed their PhD in Biology from 1998 to 2003.